Background and Importance Boosting generics is an indispensable approach in conducting cost-saving management in healthcare systems. In fact, generics can provide similar effectiveness and safety to originators but with lower costs and can increase market competition.

Aim and Objectives The purpose of this work was to demonstrate the economic advantage of a generic lenalidomide in real practice, showing and comparing costs and consumption during the period 2021 to 2022.

Material and Methods To conduct this analysis, patients, type of prescription (originator or generic), number of patients treated, number of cycles, administered milligrams and purchase prices, during the period September 2021 to August 2022, were extrapolated from pharmacy software and matched.

Results Compared with period from September 2021 to February 2022, during March to August2022, the number of treated patients remained similar (105 vs 104) and the number of cycles administered (388 vs 390).

The total expenditure of generic lenalidomide has been €147,120 and original lenalidomide €1,204,839.15, therefore the total saving has been 87.80%.

Likelihood, the generic lenalidomide has been as well tolerated as original lenalidomide.

Conclusion and Relevance Currently, cost savings and rationalisation policy are playing an essential role in healthcare systems, and generics represent a great opportunity to reallocate available resources. This study demonstrated that enhancing a generic lenalidomide is a good strategy for the sustainability of care. Lenalidomide costs decreased while the number of patients remained similar. In summary, generics constitute an efficient strategy for the sustainability of national health services, allowing resource reallocation and access to care to a larger number of patients.

References and/or Acknowledgements 1. No conflict of interest

Conflict of Interest No conflict of interest